Low level light therapy for enhancement of neurologic function by altering axonal transport rate
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61N-005/06
A61N-005/067
출원번호
US-0817090
(2010-06-16)
등록번호
US-9993659
(2018-06-12)
발명자
/ 주소
Streeter, Jackson
De Taboada, Luis
출원인 / 주소
Pthera, LLC
대리인 / 주소
Fish & Richardson P.C.
인용정보
피인용 횟수 :
0인용 특허 :
115
초록▼
Methods of altering the rate of axonal transport are provided in several embodiments. Some embodiments alter axonal transport in a patient in need of an enhancement of axonal transport to alleviate symptoms of a disease or injury. The methods further include delivering electromagnetic radiation to a
Methods of altering the rate of axonal transport are provided in several embodiments. Some embodiments alter axonal transport in a patient in need of an enhancement of axonal transport to alleviate symptoms of a disease or injury. The methods further include delivering electromagnetic radiation to at least one portion of the brain, spinal cord, or peripheral nervous system of a patient sufficient to effect an alteration in axonal transport in the patient.
대표청구항▼
1. A method for enhancing axonal transport in an impaired neuron, the method comprising: providing a low level light therapy (LLLT) device, wherein the LLLT device has a light emitting surface that emits light;identifying one or more neurons having impaired axonal transport;delivering the light to t
1. A method for enhancing axonal transport in an impaired neuron, the method comprising: providing a low level light therapy (LLLT) device, wherein the LLLT device has a light emitting surface that emits light;identifying one or more neurons having impaired axonal transport;delivering the light to the one or more neurons; anddetermining the rate of axonal transport in one or more of the one or more neurons in response to the delivery of the light and adjusting the light in response to the determined rate of axonal transport,wherein the light has a wavelength between 630 nm and 1064 nm,wherein the light has an irradiance at the light emitting surface of 10 mW/cm2 to 10000 mW/cm2, andwherein the light enhances one or more of the velocity of axonal transport in one or more of the one or more neurons, the average distance of axonal transport in one or more of the one or more neurons, and the total distance of axonal transport in one or more of the one or more neurons, thereby enhancing axonal transport in one or more of the one or more neurons. 2. The method of claim 1, wherein the light has an irradiance at or within one centimeter of one or more of the one or more neurons of 20 mW/cm2 to 60 mW/cm2. 3. The method of claim 2, wherein the light has an irradiance at or within one centimeter of one or more of the one or more neurons of 50 mW/cm2. 4. The method of claim 1, wherein the axonal transport in one or more of the one or more neurons is impaired by at least 10% as compared to axonal transport in a healthy neuron. 5. The method of claim 1, wherein the axonal transport in one or more of the one or more neurons after delivering the light is comparable to axonal transport in healthy neurons. 6. The method of claim 1, wherein the enhancement of axonal transport enhances transport of one or more mitochondria along an axon of one or more of the one or more neurons. 7. The method of claim 1, wherein the light has a wavelength of 810 nm. 8. The method of claim 1, wherein the one or more neurons comprise at least one of a peripheral neuron, sensory neuron, motor neuron, and inter neuron. 9. The method of claim 1, wherein one or more of the one or more neurons are associated with cognitive function. 10. The method of claim 1, further comprising identifying a patient having Parkinson's disease, and delivering the light to the patient. 11. The method of claim 1, further comprising: identifying a patient having a neurological impairment,wherein the neurological impairment is selected from the group consisting of Alzheimer's disease, Huntington's disease, dopaminergic impairment, and amyotrophic lateral sclerosis; anddelivering the light to the patient. 12. The method of claim 1, wherein the enhancement of axonal transport comprises increasing the rate of axonal transport. 13. The method of claim 1, wherein enhancing the rate of axonal transport comprises accelerating the clearance of a substance from one or more of the one or more neurons. 14. The method of claim 1, wherein the light is delivered continuously. 15. The method of claim 1, wherein the light is delivered in pulses. 16. A method for enhancing axonal transport in a neuron, the method comprising: providing a low level light therapy (LLLT) device, wherein the LLLT device has a light emitting surface that emits light;delivering the light to at least one neuron; anddetermining the rate of axonal transport in the neuron in response to the delivery of the light and adjusting the light in response to the determined rate of axonal transport,wherein the light has a wavelength between 630 nm and 1064 nm,wherein the light has an irradiance at or within one centimeter of the neuron of 20 mW/cm2 to 60 mW/cm2, andwherein the light enhances axonal transport in the neuron by enhancing one or more of the following: velocity of axonal transport, average distance of axonal transport, and total distance of axonal transport. 17. The method of claim 16, wherein the light is delivered in pulses at a frequency ranging from 80 to 120 Hertz. 18. A method for enhancing neuronal axonal transport in a patient having one or more symptoms of Parkinson's disease, the method comprising: identifying a patient with one or more symptoms of Parkinson's disease;providing a low level light therapy (LLLT) device, wherein the LLLT device has a light emitting surface that emits light,wherein the LLLT device is configured for delivering light to a plurality of neurons in the patient;delivering the light to the patient; anddetermining the rate of axonal transport in one or more of the plurality of neurons in response to the delivery of the light and adjusting the light in response to the determined rate of axonal transport,wherein the light has a wavelength between 630 nm and 1064 nm,wherein the light has an irradiance at the light emitting surface of 10 mW/cm2 to 10000 mW/cm2, andwherein the light enhances one or more of the velocity of axonal transport in one or more of the plurality of neurons, the average distance of axonal transport in one or more of the plurality of neurons, and the total distance of axonal transport in one or more of the plurality of neurons, thereby enhancing axonal transport in one or more of the plurality of neurons and improving one or more symptoms of Parkinson's disease. 19. The method of claim 18, wherein one or more of the plurality of neurons are dopaminergic neurons and the enhanced axonal transport increases the delivery of dopamine to the synapse of the dopaminergic neurons. 20. The method of claim 1, wherein the light has a peak irradiance at the light emitting surface of 10 mW/cm2 to 10000 mW/cm2. 21. The method of claim 1, wherein the light has a wavelength between 800 nm and 815 nm, and wherein the light has an irradiance at the light emitting surface of 1400 mW/cm2 to 4200 mW/cm2.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (115)
Gluckman, Bruce J.; Schiff, Steven J., Adaptive electric field modulation of neural systems.
Flatt James H. ; Applegate Mark A. ; Peterson Alvin, Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing replacement cartilage tissue constructs.
Seliktar Dror ; Dunkelman Noushin ; Peterson Alvin Edward ; Schreiber Ronda Elizabeth ; Willoughby Jane ; Naughton Gail K., Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage.
Lo Donald C. ; Barney Shawn ; Thomas Mary Beth ; Portbury Stuart D. ; Puranam Kasturi ; Katz Lawrence C., Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death.
Keusch Preston (New York NY) Essmyer John L. (230 Columbus Ave. Hasbroucks Heights NJ 07604), Conductive hydrogels and physiological electrodes and electrode assemblies therefrom.
Gough Anthony D. (Merseyside GBX) De Groot Joanne M. (Wirral GBX) Price Jeffrey (Merseyside GBX), Cosmetic composition comprising particles of polyisobutylene resin and process for the preparation of same.
Diamantopoulos Costas A. (31 Alexandra Mansion ; 333 Kings Road London ; SW3 5ET GBX) Alexandrou Alex P. (48 Woodland Gardens London ; N10 3UA GBX), Device for biostimulation of tissue and method for treatment of tissue.
Chan Agnes H.,CAX ; Hunt David W. C.,CAX ; Levy Julia G.,CAX ; Obochi Modestus O. K.,CAX ; Richter Anna M.,CAX ; Simkin Guillermo O.,CAX, Green porphyrins as immunomodulators.
Chaffee Edwin G. (Salt Lake City UT) Holtman Steve (Salt Lake City UT) Nelson George A. (Sandy UT) Tanner Howard M. C. (Salt Lake City UT), Laser optical delivery apparatus.
Eckhouse Shimon (Haifa ILX) Kreindel Michael (Haifa ILX), Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment.
Rochkind Simeone (5 Kashani St. Tel Aviv ILX) Barr-Nea Liliane (5 Debora Hanevia St. Tel Aviv ILX) Lubart Rachel (10 Hankin St. Tel Aviv ILX), Method for inducing regeneration of injured nerve fibers.
Modestus O. K. Obochi CA; Philippe Maria Clotaire Margaron CA; Christopher Richard Honey CA; Stephen Yip CA; Julia G. Levy CA, Method to prevent xenograft transplant rejection.
Kunkel Louis M. (Hyde Park MA) Monaco Anthony (Boston MA) Hoffman Eric P. (Newton MA) Koenig Michel (Boston MA), Probes for and nucleic acid encoding the muscular dystrophy protein, dystrophin.
Herman Stephen J. (Andover MA) Roth Laurence A. (Hudson NH) Sinofsky Edward L. (Reading MA) Dickinson ; Jr. Douglas W. (Merrimack NH), Wire guided laser catheter.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.